Zelira Therapeutics Limited (ZLDAF)
USD 0.35
(0.0%)
USD 0.35
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -233.93 Thousand AUD | 100.32% |
| 2023 | -3.21 Million AUD | -634.61% |
| 2022 | 601.57 Thousand AUD | 38.26% |
| 2021 | 435.09 Thousand AUD | 258.19% |
| 2020 | -275.05 Thousand AUD | -135.77% |
| 2019 | 769.03 Thousand AUD | 145.1% |
| 2018 | 313.75 Thousand AUD | 213.63% |
| 2017 | 100.04 Thousand AUD | -66.65% |
| 2016 | 300 Thousand AUD | 0.0% |
| 2015 | - AUD | 0.0% |
| 2014 | - AUD | 0.0% |
| 2013 | - AUD | 0.0% |
| 2012 | - AUD | 0.0% |
| 2011 | - AUD | -100.0% |
| 2010 | 34.25 Thousand AUD | 0.0% |
| 2009 | - AUD | 0.0% |
| 2008 | - AUD | -100.0% |
| 2007 | 24.92 Million AUD | 35494.25% |
| 2006 | 70.03 Thousand AUD | -82.1% |
| 2005 | 391.28 Thousand AUD | 8.77% |
| 2004 | 359.75 Thousand AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -35.63 Thousand AUD | 96.99% |
| 2024 Q2 | -1.1 Million AUD | -3000.61% |
| 2024 FY | -1.38 Million AUD | 56.84% |
| 2024 Q3 | -81.32 Thousand AUD | 92.64% |
| 2024 Q4 | -81.32 Thousand AUD | 0.0% |
| 2023 Q2 | -2.03 Million AUD | -1170.94% |
| 2023 Q1 | -159.94 Thousand AUD | 96.06% |
| 2023 FY | -3.21 Million AUD | -634.61% |
| 2023 Q3 | -15.45 Thousand AUD | 99.24% |
| 2023 Q4 | -1.18 Million AUD | -7554.53% |
| 2022 FY | 601.57 Thousand AUD | 38.26% |
| 2022 Q1 | 46.71 Thousand AUD | -58.01% |
| 2022 Q2 | -1.65 Million AUD | -3645.54% |
| 2022 Q3 | 254.07 Thousand AUD | 115.34% |
| 2022 Q4 | -4.05 Million AUD | -1697.9% |
| 2021 Q1 | 45.25 Thousand AUD | 0.0% |
| 2021 FY | 435.09 Thousand AUD | 258.19% |
| 2021 Q3 | 172.29 Thousand AUD | 280.75% |
| 2021 Q4 | 111.23 Thousand AUD | -35.44% |
| 2021 Q2 | 45.25 Thousand AUD | -0.0% |
| 2020 Q3 | - AUD | 0.0% |
| 2020 FY | -275.05 Thousand AUD | -135.77% |
| 2020 Q1 | - AUD | -100.0% |
| 2020 Q2 | - AUD | 0.0% |
| 2020 Q4 | - AUD | 0.0% |
| 2019 FY | 769.03 Thousand AUD | 145.1% |
| 2019 Q1 | - AUD | -100.0% |
| 2019 Q2 | - AUD | 0.0% |
| 2019 Q3 | 384.51 Thousand AUD | 0.0% |
| 2019 Q4 | 384.51 Thousand AUD | 0.0% |
| 2018 Q4 | 117.71 Thousand AUD | 0.0% |
| 2018 Q3 | 117.71 Thousand AUD | 200.57% |
| 2018 Q2 | 39.16 Thousand AUD | -0.0% |
| 2018 Q1 | 39.16 Thousand AUD | -21.7% |
| 2018 FY | 313.75 Thousand AUD | 213.63% |
| 2017 Q1 | - AUD | 0.0% |
| 2017 FY | 100.04 Thousand AUD | -66.65% |
| 2017 Q4 | 50.02 Thousand AUD | 0.0% |
| 2017 Q3 | 50.02 Thousand AUD | 0.0% |
| 2017 Q2 | - AUD | 0.0% |
| 2016 FY | 300 Thousand AUD | 0.0% |
| 2015 FY | - AUD | 0.0% |
| 2014 FY | - AUD | 0.0% |
| 2013 FY | - AUD | 0.0% |
| 2012 FY | - AUD | 0.0% |
| 2011 FY | - AUD | -100.0% |
| 2010 FY | 34.25 Thousand AUD | 0.0% |
| 2009 FY | - AUD | 0.0% |
| 2008 FY | - AUD | -100.0% |
| 2007 FY | 24.92 Million AUD | 35494.25% |
| 2006 FY | 70.03 Thousand AUD | -82.1% |
| 2005 FY | 391.28 Thousand AUD | 8.77% |
| 2004 FY | 359.75 Thousand AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 404.756% |
| CSL Limited | 7.56 Billion USD | 100.003% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 101.56% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 7641.393% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 101.998% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.196% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -585.019% |
| Mesoblast Limited | -35.16 Million USD | 99.335% |
| Marizyme, Inc. | 457.7 Thousand USD | 151.111% |
| Genus plc | 178.7 Million USD | 100.131% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 157.034% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -2026.673% |
| ContraFect Corporation | -154 Thousand USD | -51.905% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -367.868% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -962.29 Thousand USD | 75.69% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 39.63% |
| MultiCell Technologies, Inc. | 49.32 USD | 474418.735% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 100.581% |
| EV Biologics, Inc. | 48.9 Thousand USD | 578.393% |
| Q BioMed Inc. | -8988.00 USD | -2502.737% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 100.828% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -1416.688% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 434.191% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -88.275% |
| SQZ Biotechnologies Company | 9.79 Million USD | 102.389% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -4624.031% |
| Arch Therapeutics, Inc. | -2439.00 USD | -9491.39% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 455.912% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 266.501% |
| Neon Bloom, Inc. | - USD | Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.106% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 475.943% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -139.895% |
| GB Sciences, Inc. | -624.00 USD | -37389.423% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -171.928% |
| argenx SE | 1.1 Billion USD | 100.021% |
| HST Global, Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -112368.269% |
| Enzolytics Inc. | 30.7 Thousand USD | 861.801% |
| Resverlogix Corp. | - USD | Infinity% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 148.49% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 99.093% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 100.527% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 79.508% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 54.533% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 137.891% |
| ONE Bio Corp. | 20.12 Million USD | 101.162% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.057% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -2541.531% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -178.994% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Agentix Corp. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 62.876% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 123.678% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 102.434% |
| BioStem Technologies, Inc. | 15.42 Million USD | 101.517% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -1876.629% |
| Cell Source, Inc. | - USD | Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -384.747% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 232.495% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 232.495% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 117.237% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -706.669% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Qrons Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 151.98% |
| SYBLEU INC | 11.69 Thousand USD | 2100.12% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 26.783% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 105.077% |
| Bioxytran, Inc. | -8285.00 USD | -2723.585% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 37.283% |
| Neutra Corp. | 14.33 Thousand USD | 1731.908% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -185.285% |
| PureTech Health plc | -1.6 Million USD | 85.406% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 76.635% |
| IXICO plc | 3.27 Million USD | 107.154% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 66.292% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 86.938% |
| CSL Limited | 7.7 Billion USD | 100.003% |
| Cellectis S.A. | 18 Thousand USD | 1399.633% |